| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3,749.5 | 3,759.9 |
| Gross profit | 1,438.0 | 1,371.5 |
| Profit before tax | 127.9 | -7.9 |
| Net income | -325.3 | -128.2 |
| EPS (diluted, $ a share) | $-0.28 | $-0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -0.3% |
|---|---|
| Gross margin | 38.4% |
| Operating margin | 7.0% |
10-Q filed with the SEC, NASDAQ: VTRS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Viatris Inc: key numbers
- Share price
- $20.74Close, Nov 16
- Market cap
- $23.8B
- Shares outstanding
- 1.15BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Viatris Inc
All →Viatris Signs $1.69B M&A Deal with Pacira BioSciences, Inc.
Viatris Inc. has completed its acquisition of Pacira BioSciences, Inc. for approximately $1.69 billion in cash. The transaction was executed via a tender offer for $36.50 per share followed by a merger, establishing Viatris as a leader in non-opioid pain management.
- Value
- $1.69B
- Counterparty
- Pacira BioSciences, Inc.
“Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business. With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management. We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth.”
Scott A. Smith, CEO of Viatris
Viatris Financial Results
Viatris reported Q3 2026 total revenues of $3.75 billion and raised its full-year 2026 financial guidance midpoints across all metrics. The company reported a GAAP net loss of $325.3 million, primarily driven by operational momentum in higher-margin businesses and progress in its innovative medicines strategy, including the pending acquisition of Pacira BioSciences.
- Term
- Q3 2026
“Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business. Momentum across key areas of our base business, progress in our pipeline and the benefits of our enterprise-wide strategic review continue to strengthen our company.”
Scott A. Smith, CEO, Viatris
“We are very pleased with the operational momentum across our higher-margin businesses and continued focus on cost discipline, which led to strong overall third-quarter results. Based on this performance and our confidence in the outlook for the rest of the year, we are once again raising the midpoints of our financial guidance ranges across all key metrics.”
Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris
Viatris Signs $1.65B M&A Deal with Pacira BioSciences, Inc.
Viatris Inc. has entered into a definitive agreement to acquire Pacira BioSciences for $36.50 per share in cash, representing an aggregate equity value of approximately $1.65 billion. The acquisition adds two marketed non-opioid pain therapies, EXPAREL and ZILRETTA, to Viatris' portfolio and is expected to close by the end of 2026.
- Value
- $1.65B
- Counterparty
- Pacira BioSciences, Inc.